Overweight: Clinical Trials

380 trials for Overweight, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

380 completed. 380 Phase 3, 86 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3380Completed 380
Phase 286Completed 86

Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight

Trials (filtered) newest first · largest first

All 380 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
GZR18 injection, Placebo - Overweight or Obesity
Phase 3CompletedGan & Lee Pharmaceuticals.2242026-01-222026-11-10
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
Dulaglutide, Semagludtide, Tirzepatide - Non-diabetec Obesity, Obesity (Disorder)
Phase 3CompletedZagazig University1502025-11-142026-09-22
Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial
Dulaglutide 1.5 MG/ML, Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Tirzepatide is administered as part of routine clinical care for obesity management, according to standard prescribing practices. Dosing and treatment duration are determined by the treating physician - Obese Diabetics, Obese Non Diabetic
Phase 3CompletedZagazig University1592025-10-182026-09-15
A Trial of HRS-7535 Tablets in Subjects With Overweight or Obesity
HRS-7535 Tablets, HRS-7535 Placebo Tablets - Overweight, Obesity
Phase 3CompletedShandong Suncadia Medicine Co., Ltd.5562025-04-102026-07-27
A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
TQF3510 (Semaglutide Injection), Wegovy® - Obesity
Phase 3CompletedChia Tai Tianqing Pharmaceutical Group Co., Ltd.4082025-03-202026-09-25
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
Metformin with Semaglutide - Polycystic Ovary Syndrome (PCOS) Women, Obesity
Phase 2 / Phase 3CompletedBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh312025-01-012026-10-07
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
GZR18, Placebo - Obesity/Overweight
Phase 3CompletedGan & Lee Pharmaceuticals.6402024-12-302026-11-12
A Research Study of VCT220 in Adult Chinese Participants With Obesity
VCT220, Placebo - Obesity, Overweight
Phase 3CompletedVincentage Pharma Co., Ltd8402024-12-242026-09-16
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
mibavademab - Generalized Lipodystrophy
Phase 3CompletedRegeneron Pharmaceuticals92024-12-162026-07-29
A Study of HS-20094 in Chinese Adults With Overweight or Obesity
HS-20094 injection, Placebo injection - Overweight, Obesity
Phase 3CompletedJiangsu Hansoh Pharmaceutical Co., Ltd.6042024-11-162026-06-08
A Study of BGM0504 Injection in Participants With Obesity or Overweight
5 mg BGM0504 injection, 10 mg BGM0504 injection administered subcutaneously (SC) once a week, 15 mg BGM0504 injection - Overweight or Obesity
Phase 3CompletedBrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.6522024-10-292026-10-15
A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Orforglipron, Placebo - OSA, Overweight or Obesity
Phase 3CompletedEli Lilly and Company7122024-10-222026-09-14
Open-Label Extension Study of Setmelanotide
Setmelanotide - Obesity Associated With Defects in Leptin-melanocortin Pathway
Phase 3CompletedRhythm Pharmaceuticals, Inc.282024-10-212026-07-15
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Ixekizumab, Tirzepatide - Psoriasis, Obesity
Phase 3CompletedEli Lilly and Company2812024-09-302026-06-17
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Ixekizumab, Tirzepatide - Psoriatic Arthritis, Obesity
Phase 3CompletedEli Lilly and Company2792024-09-242026-05-13
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Orforglipron, Placebo - Obesity, Overweight
Phase 3CompletedEli Lilly and Company3762024-09-132026-06-04
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Cagrilintide, Semaglutide, Placebo - Obesity
Phase 3CompletedNovo Nordisk A/S3002024-06-242026-05-05
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
Essential Amino Acid Supplement by Amino Co, Placebo - Hepatic Steatosis, NAFLD
Phase 3CompletedUniversity of Colorado, Denver312024-06-182026-08-31
To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese
HRS9531 injection, Placebo - Overweight or Obesity
Phase 3CompletedFujian Shengdi Pharmaceutical Co., Ltd.5672024-05-132025-07-11
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)
Survodutide, Placebo - Obesity, Non-Alcoholic SteatoHepatitis (NASH)
Phase 3CompletedBoehringer Ingelheim2182024-04-022026-04-30

Showing 20 of 380. Sign in to see all of them.

Narrower conditions

Obesity (336)  ·  Diabetes Mellitus, Type 2 (48)  ·  Weight Loss (35)  ·  Motor Activity (31)  ·  Hypertension (24)  ·  Insulin Resistance (19)  ·  Diabetes Mellitus (18)  ·  Cardiovascular Diseases (17)  ·  Metabolic Syndrome (17)  ·  Nutrition Disorders (17)  ·  Obesity, Morbid (15)  ·  Binge-Eating Disorder (12)  ·  Dyslipidemias (12)  ·  Prader-Willi Syndrome (10)

Broader conditions

Nutritional and Metabolic Diseases (380)  ·  Overnutrition (380)  ·  Pathological Conditions, Signs and Symptoms (369)  ·  Signs and Symptoms (368)  ·  Nutrition Disorders (363)  ·  Body Weight (361)  ·  Metabolic Diseases (103)  ·  Glucose Metabolism Disorders (92)  ·  Endocrine System Diseases (79)  ·  Diabetes Mellitus (50)  ·  Body Weight Changes (37)  ·  Behavior (36)  ·  Hyperinsulinism (35)  ·  Nervous System Diseases (32)

Interventions

semaglutide (37)  ·  Exercise (18)  ·  Tirzepatide (15)  ·  Liraglutide (14)  ·  Metformin (13)  ·  Diet (10)  ·  Topiramate (9)  ·  Rimonabant (8)  ·  sibutramine (8)  ·  bupropion hydrochloride, naltrexone hydrochoride drug combination (7)  ·  setmelanotide (7)  ·  Exenatide (6)  ·  BI 456906 (5)  ·  Diet, Reducing (5)  ·  cagrilintide (5)

Sponsors

Novo Nordisk A/S (35)  ·  Eli Lilly and Company (21)  ·  Yale University (13)  ·  Sanofi (8)  ·  Boehringer Ingelheim (7)  ·  Mayo Clinic (7)  ·  Rhythm Pharmaceuticals, Inc. (7)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (6)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (6)  ·  Abbott (5)  ·  Orexigen Therapeutics, Inc (5)  ·  The Miriam Hospital (5)  ·  Assistance Publique - Hôpitaux de Paris (4)  ·  University of Colorado, Denver (4)  ·  VIVUS LLC (4)

Countries

United States (197)  ·  Canada (43)  ·  France (36)  ·  Germany (36)  ·  United Kingdom (35)  ·  Spain (32)  ·  China (31)  ·  Puerto Rico (23)  ·  Brazil (22)  ·  Mexico (22)  ·  Italy (20)  ·  Japan (20)  ·  Taiwan (20)  ·  Australia (19)  ·  South Korea (19)

Top investigators

David Meeker, MD (7)  ·  Craig Peterson (4)  ·  Dennis T Villareal, MD (4)  ·  Allison B. Goldfine, MD (3)  ·  Barbara Grube, MD (3)  ·  Carlos M Grilo, Ph.D. (3)  ·  Kathleen Jablonski, PhD (3)  ·  Kishore Gadde, MD (3)

Results publications

PMID 27482610, PMID 27817208, PMID 28386912, PMID 28950422, PMID 30122305, PMID 38698650, PMID 39226070, PMID 23661689, PMID 26418188, PMID 27206567, PMID 27659698, PMID 27888609, PMID 28455281, PMID 28473337, PMID 35724304, PMID 36801984, PMID 40717199, PMID 41187013, PMID 41537305, PMID 41885866, PMID 42821228, PMID 26744025, PMID 26833744, PMID 27116910, PMID 27193270, PMID 27804269, PMID 28462892, PMID 33137293, PMID 33567185, PMID 33667417, PMID 36200477, PMID 37605636, PMID 37919617, PMID 38671361, PMID 39222642, PMID 39316288, PMID 39800653, PMID 40512543, PMID 40980163, PMID 41640675, PMID 42014131, PMID 42348366, PMID 12439645, PMID 15486569, PMID 15536230, PMID 15836887, PMID 16018851, PMID 16291982, PMID 16478899, PMID 16636211

NIH funding

2017 (7), 2023 (6), 2008 (3), R01DK049587 (3), R01DK114075 (3), R01DK126637 (3), 2014 (2), 2018 (2), R01AG025501 (2), R18DK083248 (2), U01DK074556 (2), 1RC1DK086132 (1), 2015 (1), 2016 (1), 2019 (1)